Business
NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting
Three-year data from NeuroPace’s Post-Approval Study of the RNS® System in drug-resistant focal epilepsy to be shared in oral presentationMOUNTAIN VIEW, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, will be attending and presenting at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting, which is being held in San Diego from April 5 – 9. This includes an oral pr
About this update from Neuropace, Inc.
[{"type":"image","alt":"NeuroPace, Inc.","displaySize":"","headline":null,"caption":"NeuroPace, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":52,"url":"https://media.zenfs.com/en/globenewswire.com/49cad5934d5ea78febfb7e12e9a6509b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5Q0OXhSfgqHpvUIbwQZadQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTczO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/49cad5934d5ea78febfb7e12e9a6509b","width":300,"height":52}},"lazy":false},{"type":"text","content":"Three-year data from NeuroPace’s Post-Approval Study of the RNS® System in drug-resistant focal epilepsy to be shared in oral presentation","length":138,"tagName":"p"},{"type":"text","content":"MOUNTAIN VIEW, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, will be attending and presenting at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting, which is being held in San Diego from April 5 – 9. This includes an oral presentation on data from the Post-Approval Study (PAS) of the RNS® System in adults treated with brain-responsive stimulation for drug-resistant focal epilepsy (DRE) on Monday, April 7.","length":546,"tagName":"p"},{"type":"text","content":"“Drug-resistant focal epilepsy means patients do not respond to drug therapy and often face a lifetime of debilitating seizures from the time of childhood or adolescence,” said Joel Becker, NeuroPace’s Chief Executive Officer. “It remains a significant unmet medical need, and we are committed to helping people with DRE. We look forward to sharing insights and presenting data that may have an impact on this patient population at AAN 2025.”","length":442,"tagName":"p"},{"type":"text","content":"The RNS System is the first and only neuromodulation platform that delivers personalized, real-time seizure treatment and will be on display in booth #1642. NeuroPace presentations and activities at the 2025 AAN Annual Meeting include:","length":245,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Oral Presentation: Multicenter Post-Approval Study of the RNS System in Focal Epilepsy","length":86,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Monday, April 7 5:06 – 5:18PM PDT | SDCC Room...